Shenzhen Hightide Biopharmaceutical Ltd. has identified new peroxisome proliferator-activated receptor δ (PPARδ) and PPARα dual agonists potentially useful for the treatment of obesity, aging, cardiovascular disorders, heart failure, inflammatory disorders, metabolic dysfunction-associated steatotic liver disease (MASLD; NAFLD), metabolic syndrome and renal failure.

Pfizer Inc. has reported new biaryl acid compounds acting as phosphatidylinositol 3-kinase α (PI3Kα) H1047R mutant inhibitors potentially useful for the treatment of cancer.

Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders, schizophrenia, obesity, sleep disorders, post-traumatic stress, substance abuse and dependence, among others.

Assembly Biosciences Inc. has divulged new dihydroquinazolines potentially useful for the treatment of cytomegalovirus (CMV) infections.

Incyte Corp. has synthesized new GTPase KRAS inhibitors potentially useful for the treatment of cancer, inflammatory and immunological disorders.

Changchun Genescience Pharmaceuticals Co. Ltd. has discovered new ubiquitin carboxyl-terminal hydrolase 30 (USP30) inhibitors potentially useful for the treatment of mitochondrial and Parkinson’s disease.

Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has reported new proteolysis targeting chimera (PROTACs) compounds comprising a cereblon E3 ubiquitin ligase-binding moiety covalently linked to a eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1)-targeting moiety potentially useful for the treatment of cancer.

Chomix Biotech (Nanjing) Co. Ltd. has patented new irreversible fibroblast activation protein-α (FAPα) inhibitors potentially useful for the diagnosis or treatment of rheumatoid arthritis, atherosclerosis, cancer, myocardial infarction, kidney fibrosis, pulmonary and hepatic fibrosis, and among others.

Synnovation Therapeutics Inc. has identified new heterocyclic poly(ADP-ribose) glycohydrolase (PARG) inhibitors described as useful for the treatment of cancer.

Bristol Myers Squibb Co. (BMS) has disclosed new 1H-benzo[d]imidazole derivatives acting as calcium/calmodulin-dependent protein kinase type II (CAMK2) inhibitors potentially useful for the treatment of anxiety disorders, asthma, cardiomyopathy, diabetes, fibrosis, heart failure, hypertension and allergy, among others.